Our work on COVID-19 antibodies was covered by insideBIGDATA. They did a fantastic job covering the piece originally published by Columbia Data Science Institute, highlighting a few choice gems.

What our algorithms do is reduce the likelihood of drug-discovery failure in the lab,” he adds. “We fail in the computer as much as possible to reduce the possibility of downstream failure in the laboratory. And that shaves a significant amount of time from laborious and time-consuming work. We are building a company that sits at the frontiers of AI and biotech. We are hard at work accelerating the speed at which healing is discovered and delivered and could not ask for a more fulfilling mission.

Read the entire article here.